Trending...
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
- From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
PHILADELPHIA, April 9, 2021 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, a first-in-class anti-cancer agent, announced that Sandra Van Schaeybroeck, PhD (Queen's University Belfast) will be presenting research supporting BOLD-100 as a potential anti-resistance therapy for difficult-to-treat cancers, specifically BRAF-mutant colorectal cancer.
Van Schaeybroeck's AACR poster presentation "Targeting the DNA repair pathway with BOLD-100 in BRAF-mutant colorectal cancer" (Poster# 1183, Session PO.ET04.03 on April 10) highlights the promising research conducted by the Drug Resistance Group at the Patrick G. Johnston Centre for Cancer Research at Queen's University Belfast, which investigated BOLD-100's mechanism-of-action and identified promising treatment combinations in difficult-to-treat BRAF mutant colorectal cancers.
"BOLD-100 has a unique and complex mechanism-of-action and has potential in various challenging cancer subtypes, such as V600E BRAF-mutated colorectal cancer," stated Van Schaeybroeck. "This study further elucidated the mechanism-of-action for BOLD-100 and identified potentially synergistic drug-drug combinations for future investigation."
More on The PennZone
The AACR Annual Meeting provides an opportunity to discuss the latest discoveries in cancer research and highlights the work being done by institutions around the world. This year's virtual conference is taking place April 10-15 and May 17-21.
"Bold Therapeutics has developed a global consortium of world-class academic collaborators to investigate the potential of BOLD-100 as a revolutionary first-in-class anti-cancer agent that targets both ER stress and DNA repair pathways," said Mark Bazett, PhD, Director of Preclinical Development at Bold Therapeutics. "We look forward to connecting with interested researchers at AACR 2021 to further develop this novel therapy."
Bold Therapeutics is headquartered in Vancouver, British Columbia, Canada. BOLD-100 is currently being investigated in a Phase 1b/2 study in combination with FOLFOX in the treatment of advanced gastrointestinal cancers at six sites in Canada, with additional sites opening in the United States and South Korea in late 2021.
For more information, please visit the Company's website at www.bold-therapeutics.com or the AACR conference website https://www.aacr.org/meeting/aacr-annual-meeting-2020/
Source: Bold Therapeutics, Inc.
Contact:
E. Russell McAllister, CEO
(604) 262-9899
[email protected]
SOURCE Bold Therapeutics Inc.
Van Schaeybroeck's AACR poster presentation "Targeting the DNA repair pathway with BOLD-100 in BRAF-mutant colorectal cancer" (Poster# 1183, Session PO.ET04.03 on April 10) highlights the promising research conducted by the Drug Resistance Group at the Patrick G. Johnston Centre for Cancer Research at Queen's University Belfast, which investigated BOLD-100's mechanism-of-action and identified promising treatment combinations in difficult-to-treat BRAF mutant colorectal cancers.
"BOLD-100 has a unique and complex mechanism-of-action and has potential in various challenging cancer subtypes, such as V600E BRAF-mutated colorectal cancer," stated Van Schaeybroeck. "This study further elucidated the mechanism-of-action for BOLD-100 and identified potentially synergistic drug-drug combinations for future investigation."
More on The PennZone
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
- CLASS ACTION REMINDER: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Lawsuit by August 25, 2025
- Colbert Packaging Announces WBENC Recognition
- SHI Cryogenics Group Launches Highest-Capacity Single-Stage Cryocoolers to Date
The AACR Annual Meeting provides an opportunity to discuss the latest discoveries in cancer research and highlights the work being done by institutions around the world. This year's virtual conference is taking place April 10-15 and May 17-21.
"Bold Therapeutics has developed a global consortium of world-class academic collaborators to investigate the potential of BOLD-100 as a revolutionary first-in-class anti-cancer agent that targets both ER stress and DNA repair pathways," said Mark Bazett, PhD, Director of Preclinical Development at Bold Therapeutics. "We look forward to connecting with interested researchers at AACR 2021 to further develop this novel therapy."
Bold Therapeutics is headquartered in Vancouver, British Columbia, Canada. BOLD-100 is currently being investigated in a Phase 1b/2 study in combination with FOLFOX in the treatment of advanced gastrointestinal cancers at six sites in Canada, with additional sites opening in the United States and South Korea in late 2021.
For more information, please visit the Company's website at www.bold-therapeutics.com or the AACR conference website https://www.aacr.org/meeting/aacr-annual-meeting-2020/
Source: Bold Therapeutics, Inc.
Contact:
E. Russell McAllister, CEO
(604) 262-9899
[email protected]
SOURCE Bold Therapeutics Inc.
Filed Under: Business
0 Comments
Latest on The PennZone
- Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft
- Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
- Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
- LDR Partners LP Announces Acquisition of Active Radiator, and Combination with Cincinnati Radiator and Ohio Heat Transfer, Forming the Largest U.S. Heavy Manufacturing Platform for Aluminum Industrial Heat Exchangers
- $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co
- Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
- Radarsign Tackles Intersection Safety with Launch of Grid-Free Solar LED Stop Sign
- Sidney and Caroline Kimmel Invest in the Future of Care and Discovery at Jefferson
- Abide Capital Acquires Columbus, OH Apartment Community for $16.5 Million
- Miami Real Estate Agent Drastically Increases Interest In Homes
- Adostics & Genmega Announce the Introduction of A-POD
- QVC Kicks Off 'Christmas in July' with Star-Studded Merrymakers Lineup: Elton John, Martha Stewart, Kathy Hilton, Kim Gravel and Babs Costello as Chief Cheer Officer
- LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
- Heritage at South Brunswick Offers Immediate Townhome Appointments and Special Mortgage Incentive Fast-Moving Sales
- INVESTIGATION ALERT: Berger Montague PC Investigates Aflac, Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: AFL)
- The Waite Launches: A Curated Motherhood Marketplace For Every Stage
- Affordable, High-Quality Care: Cheap Braces for Adults Available from Exeter Smiles in Reading
- NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
- Sci-Fi Novel from Pittsburgh Author Explores Love, Power, & Humanity in an Age of Artificial People
- Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media